MichaelKeeferMD

Infectious Disease • Rochester, NY

Professor of Medicine University of Rochester School of Medicine & Dentistry

Join to view full profile

Dr. Keefer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Keefer's full profile

Already have an account?

Office
601 Elmwood Ave
# Box
Rochester, NY 14642
Phone+1 585-275-5871

Fax+1 585-273-1055

Education & Training

University of RochesterFellowship, Infectious Disease, 1987 - 1990
Christ HospitalResidency, Internal Medicine, 1983 - 1986
Wright State University Boonshoft School of MedicineClass of 1983

Certifications & Licensure

NY State Medical License 1987 - 2025
OH State Medical License 1984 - 1988
American Board of Internal Medicine Internal Medicine

Clinical Trials

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers
Completed
Phase 1
Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults Start of enrollment: 2004 Sep 01
Completed
Phase 1
HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants Start of enrollment: 2005 Sep 01
Completed
Phase 2
Safety and Immunogenicity of a Plasmid HIV Vaccine in HIV Uninfected Adults Start of enrollment: 2003 Dec 01
Completed
Phase 1
Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults Start of enrollment: 2005 Jan 01
Completed
Phase 1
A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers Start of enrollment: 2009 Mar 01
Completed
Phase 1
A Trial to Evaluate an HIV Envelope Trimer, N332-GT5 gp140, Adjuvanted With SMNP in Adult Participants Without HIV Start of enrollment: 2023 Nov 27
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120.
Zvavahera Mike Chirenje, Fatima Laher, One Dintwe, Monde Muyoyeta, Allan C deCamp
The Journal of Infectious Diseases. 2024-08-16
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected ad...
Ian Frank, Shuying S Li, Nicole Grunenberg, Edgar T Overton, Samuel T Robinson
The Lancet. HIV. 2024-05-01
1 citations
Daily fosfomycin versus levofloxacin for complicated urinary tract infections.
Nadine Rouphael, Patricia Winokur, Michael C Keefer, Jessica Traenkner, Ana Drobeniuc
Mbio. 2023-10-31

Press Mentions

URMC Wins $18 Million Grant for HIV EffortsDecember 8th, 2020
More Volunteers Needed in COVID-19 Vaccine Research TrialsDecember 1st, 2020
Doctors Ask for More Volunteers in Vaccine Research Trials Through the HolidaysNovember 30th, 2020
Join now to see all